Answers are grounded in this paper and cite their sources.
This review explores the evolving landscape of antifungal management, moving beyond "one-size-fits-all" approaches to personalized, risk-stratified strategies. It begins by defining prophylaxis, empiric, and preemptive therapies, emphasizing the need for tailored interventions. A comprehensive review of modern risk assessment follows, covering host, environmental, and treatment-related factors, as well as emerging pathogens and available predictive models. Antifungal prophylaxis is discussed in more detail, considering patient selection, agent choice, duration, and the critical balance between risk reduction and potential harms. Diagnostic-driven strategies are presented as key to reducing antifungal exposure and resistance without increasing harm. Special scenarios, such as antifungal prophylaxis in COVID-19 and resource-limited settings, are discussed, along with future perspectives on the use of artificial intelligence and next-generation diagnostics.
No takes yet. Share an insight, caveat, or question.
Gonzales et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: